Neuberger Berman Group
AXDX

Neuberger Berman Group’s Accelerate Diagnostics AXDX Stock Holding History

Neuberger Berman Group’s Portfolio AXDX Stock Details AXDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-1,355
Closed -$371K – 1600
2017
Q2 		$371K Sell
1,355
-60
-4% -$16.3K ﹤0.01% 1367
2017
Q1 		$342K Hold
1,415
– – ﹤0.01% 1391
2016
Q4 		$294K Sell
1,415
-635
-31% -$151K ﹤0.01% 1421
2016
Q3 		$559K Sell
2,050
-2,750
-57% -$608K ﹤0.01% 1246
2016
Q2 		$691K Hold
4,800
– – ﹤0.01% 1175
2016
Q1 		$690K Sell
4,800
-50
-1% -$7.06K ﹤0.01% 1182
2015
Q4 		$1.04M Buy
4,850
+2,685
+124% +$490K ﹤0.01% 1120
2015
Q3 		$350K Buy
+2,165
New +$468K ﹤0.01% 1354

Other funds holding AXDX

OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $214M AUM 185.33% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CC
Cannell & Co New York $3.15B AUM 30.62% 1-Year Est. Return
PC
Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return
MGM
Miura Global Management New York $25.2M AUM 60.6% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $38.4B AUM 25.71% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return

Neuberger Berman Group's AXDX Position: Q3 2017 in Review

Neuberger Berman Group sold out of Accelerate Diagnostics (AXDX) in Q3 2017, closing a stake of 1,355 shares — an estimated $371K sold.

Neuberger Berman Group first reported a position in AXDX in Q3 2015 and held it in 8 quarters. The position peaked at $1.04M in Q4 2015. 118 funds tracked by Wall St. Rank hold AXDX as of Q3 2017.

  • Neuberger Berman Group reported no remaining Accelerate Diagnostics position as of Q3 2017 after selling out during the quarter.
  • Neuberger Berman Group sold 1,355 Accelerate Diagnostics shares in Q3 2017, an estimated $371K.
  • Neuberger Berman Group first reported a position in Accelerate Diagnostics in Q3 2015 and held it in 8 quarters.
  • Neuberger Berman Group's Accelerate Diagnostics position peaked at $1.04M in Q4 2015.
  • 118 funds tracked by Wall St. Rank held Accelerate Diagnostics as of Q3 2017.

Based on Neuberger Berman Group's 13F filing for Q3 2017, filed 15 Nov 2017.